Overview
Virtual Patient Encounters: Improving Outcomes in Colorectal Cancer Patients
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This educational activity is designed for physicians and other clinicians who manage and treat patients with CRC.
Despite the decreased mortality rates associated with colorectal cancer (CRC), it remains the third most commonly diagnosed cancer and the third leading cause of cancer-related death for both men and women in the US. Furthermore, only half of those aged 50 and older, for whom screening is recommended, report undergoing a CRC screen. Moreover, an estimated 20% of patients diagnosed with CRC have an advanced form of the disease. Advances in the utilization of biological agents and evolving surgical management techniques have the potential to improve patient outcomes. Thus, a case-based learning format that leads to appropriate screening, management and use of optimized treatment strategies for advanced stages of CRC is essential to expanding clinicians’ knowledge and competency with regard to treating and managing patients with this disease.
Upon completion of this activity, participants will be able to
- Evaluate the safety and efficacy of monoclonal antibody therapies in the first-line and maintenance treatment of CRC
- Assess the utility of adjuvant therapy in patients with early and late-stage CRC
- Incorporate individual patient characteristics, risk factors, and comorbidities when formulating personalized treatment regimens for CRC
Cosponsored by Indiana University School of Medicine and The Academy for Continued Healthcare Learning
This activity is supported by educational grants from Genentech and Lilly USA, LLC
Cathy Eng, MD, FACP
Associate Professor
Department of Gastrointestinal (GI) Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Associate Professor
Department of Gastrointestinal (GI) Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Indiana University School of Medicine requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. Conflict resolution must occur prior to the CME/CE activity. Indiana University School of Medicine also requires participating faculty to disclose when unapproved/unlabeled uses of a product are discussed in a CME/CE activity. This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. Indiana University School of Medicine requires the speaker to disclose that a product is not labeled for the use under discussion. The provider’s documentation of common practices that make the disclosure requirement known to faculty demonstrates compliance with ACCME guidelines.
The planning committee and faculty members have provided the following disclosure information.
Cathy Eng, MD, FACP (Chair) Type of financial relationships:
Sources of Funding for Research: Daiichi Sankyo, Inc.; Keryx Biopharmaceuticals, Inc.
Consulting Agreements: Bayer HealthCare Pharmaceuticals
All conflicts of interest have been resolved through independent peer-review of the content to be presented.
The planning committee and faculty members have provided the following disclosure information.
Cathy Eng, MD, FACP (Chair) Type of financial relationships:
Sources of Funding for Research: Daiichi Sankyo, Inc.; Keryx Biopharmaceuticals, Inc.
Consulting Agreements: Bayer HealthCare Pharmaceuticals
All conflicts of interest have been resolved through independent peer-review of the content to be presented.
All Academy for Continued Healthcare Learning and Indiana University School of Medicine staff members, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
This activity utilizes a digital platform that enables learners to explore three patient profiles (case-based learning) that present some of the challenges clinicians may encounter when treating patients with CRC.
It has been determined that this online activity can be completed in 30 minutes. To receive credit, participants must complete the pre-assessment survey, review the learning objectives and faculty disclosures, view all 3 patient profiles, reflect on the content, and complete the post-assessment survey and evaluation. A certificate of credit will be immediately available once these requirements are met. There is no fee to participate in the program or for the generation of the certificate.
It has been determined that this online activity can be completed in 30 minutes. To receive credit, participants must complete the pre-assessment survey, review the learning objectives and faculty disclosures, view all 3 patient profiles, reflect on the content, and complete the post-assessment survey and evaluation. A certificate of credit will be immediately available once these requirements are met. There is no fee to participate in the program or for the generation of the certificate.
Hardware and Software Requirements |
An active Internet connection (DSL or Cable). A wireless, dial-up, or slow connection may have constant buffering problems. Windows
Mac OS
|
Indiana University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Indiana University School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |